In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates
Open Access
- 1 March 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (3) , 1068-1071
- https://doi.org/10.1128/aac.47.3.1068-1071.2003
Abstract
Caspofungin is an echinocandin antifungal agent with broad-spectrum activity against Candida and Aspergillus spp. The in vitro activities of caspofungin against 3,959 isolates of Candida spp. obtained from over 95 different medical centers worldwide were compared with those of fluconazole and itraconazole. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the NCCLS method using RPMI 1640 as the test medium. Caspofungin was very active against Candida spp. (MIC at which 90% of the isolates were inhibited [MIC90], 1 μg/ml; 96% of MICs were ≤2 μg/ml). Candida albicans, C. dubliniensis, C. tropicalis, and C. glabrata were the most susceptible species of Candida (MIC90, 0.25 to 0.5 μg/ml), and C. guilliermondii was the least susceptible (MIC90, >8 μg/ml). Caspofungin was very active against Candida spp., exhibiting high-level resistance to fluconazole and itraconazole (99% of MICs were ≤1 μg/ml). These results provide further evidence for the spectrum and potency of caspofungin activity against a large and geographically diverse collection of clinically important isolates of Candida spp.Keywords
This publication has 31 references indexed in Scilit:
- Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy MenAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium sppAntimicrobial Agents and Chemotherapy, 2002
- Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan AntigenemiaAntimicrobial Agents and Chemotherapy, 2002
- A Randomized, Double‐Blind, Double‐Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised PatientsClinical Infectious Diseases, 2001
- Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in RabbitsAntimicrobial Agents and Chemotherapy, 2001
- Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2000
- International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agentsDiagnostic Microbiology and Infectious Disease, 1999
- Activity of MK-0991 (l-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.Diagnostic Microbiology and Infectious Disease, 1998
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.Diagnostic Microbiology and Infectious Disease, 1996